Search results for "Valine"

showing 10 items of 85 documents

1H NMR-based metabolomics studies of urine reveal differences between type 1 diabetic patients with high and low HbAc1 values

2012

Abstract The aim of this study was to investigate relation between level of HbAc1 and concentration of metabolites in urine of T1D patients. To test this hypothesis the 1 H NMR (proton nuclear magnetic resonance) target analysis of crucial urine metabolites combined with chemometric approach were applied. Urine samples were collected from 30 children and teenagers aged 4–19 with T1D and 12 healthy children, aged 9, as control group. Patients were divided into two groups according to their level of glycated hemoglobin (HbA1c): below (L-T1D) and above 6.5% (H-T1D). The multivariate data analysis (OPLS-DA) was used to explore data and generate the models for selected groups of patients. Two ta…

MaleMagnetic Resonance SpectroscopyAdolescentendocrine system diseasesMetaboliteClinical BiochemistryPharmaceutical ScienceTarget analysisUrineAnalytical ChemistryYoung Adultchemistry.chemical_compoundMetabolomicsValineDrug DiscoveryHumansMetabolomicsAmino AcidsChildSpectroscopyGlycated HemoglobinAlanineChromatographynutritional and metabolic diseasesDiabetes Mellitus Type 1GlucosechemistryBiochemistryChild PreschoolProton NMRFemaleGlycated hemoglobinJournal of Pharmaceutical and Biomedical Analysis
researchProduct

A model-based meta-analysis of sofosbuvir-based treatments in chronic hepatitis C patients.

2016

The objective of this study was to compare the efficacy of sofosbuvir-based treatments in patients with chronic hepatitis C virus (HCV) infection using a model-based meta-analysis (MBMA). A bibliographic search was performed to identify clinical trials involving sofosbuvir as a unique direct-acting antiviral (DAA) agent or together with daclatasvir, ledipasvir or simeprevir for the treatment of diagnosed HCV infection. The time course of the virological response (VR) was modelled to estimate the effect of treatment and the influence of population characteristics on the longitudinal efficacy profile. The model was validated and simulations of 10 different treatment schedules were performed. …

MaleMicrobiology (medical)OncologyLedipasvirSimeprevirmedicine.medical_specialtyPyrrolidinesDaclatasvirSofosbuvirHepatitis C virusPopulationHepacivirusPharmacologymedicine.disease_causeAntiviral Agents03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSimeprevirInternal medicinemedicineHepatitis C virus Meta-analysis Modelling Simulation SofosbuvirHumansPharmacology (medical)030212 general & internal medicineeducationFluoreneseducation.field_of_studybusiness.industryImidazolesValineGeneral MedicineHepatitis C ChronicModels TheoreticalClinical trialInfectious DiseaseschemistryMeta-analysisBenzimidazolesDrug Therapy CombinationFemale030211 gastroenterology & hepatologyCarbamatesSofosbuvirbusinessmedicine.drug
researchProduct

High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Geno…

2015

BACKGROUND Few direct anti-hepatitis C virus (HCV) agents have been studied in difficult-to-treat null responder and cirrhotic human immunodeficiency virus (HIV)-coinfected patients. Daclatasvir and asunaprevir combined with pegylated interferon/ribavirin (peg-IFN/RBV) have shown promising results in HCV-monoinfected patients. METHODS An open-label, single-arm, phase 2 study was conducted in HIV/HCV genotype 1/4-coinfected patients who were null responders to prior peg-IFN/RBV standard therapy and on a raltegravir-based regimen with HIV RNA <400 copies/mL. They received a 4-week lead-in phase with peg-IFN/RBV, followed by 24 weeks of asunaprevir (100 mg twice daily), daclatasvir (60 mg once…

MaleMicrobiology (medical)medicine.medical_specialtyPyrrolidinesDaclatasvir[SDV]Life Sciences [q-bio]PopulationHIV InfectionsHepacivirusAntiviral AgentsGastroenterologychemistry.chemical_compoundPegylated interferonInternal medicinemedicineHumansdaclatasvireducationasunaprevireducation.field_of_study[ SDV ] Life Sciences [q-bio]Coinfectionbusiness.industryRibavirincirrhosisImidazolesvirus diseasesHIVValineHepatitis C ChronicMiddle AgedRaltegravirmedicine.disease3. Good healthRegimenTreatment OutcomeInfectious DiseaseschemistryImmunologyHCVCoinfectionAsunaprevirFemaleCarbamatesbusinessmedicine.drug
researchProduct

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

2001

Researchers worldwide with information about the Kirsten ras (Ki-ras) tumour genotype and outcome of patients with colorectal cancer were invited to provide that data in a schematized format for inclusion in a collaborative database called RASCAL (The Kirsten ras in-colorectal-cancer collaborative group). Our results from 2721 such patients have been presented previously and for the first time in any common cancer, showed conclusively that different gene mutations have different impacts on outcome, even when the mutations occur at the same site on the genome. To explore the effect of Ki-ras mutations at different stages of colorectal cancer, more patients were recruited to the database, whi…

MaleOncologyCancer ResearchPathologyMultivariate analysisDatabases FactualSettore MED/06 - Oncologia MedicaColorectal cancerGene mutationmedicine.disease_cause0302 clinical medicineGenotypeColorectal cancer Ki-ras mutationRegistriesAged 80 and over0303 health sciencesMutationValineMiddle Aged3. Good healthKRAS Mutation Analysismedicine.anatomical_structureOncologyPresented by the Kirsten ras in-colorectal-cancer collaborative group030220 oncology & carcinogenesisFemaleColorectal NeoplasmsAdultmedicine.medical_specialtyAdolescentGenotypeoverall survivalMutation MissenseRectumcolorectal cancerDisease-Free Survival03 medical and health sciencesInternal medicinemedicineHumansPoint MutationK-rasCodoncolorectal cancer; K-ras; prognosis; overall survivalAgedNeoplasm StagingProportional Hazards Models030304 developmental biologybusiness.industryCancermedicine.diseaseSurvival AnalysisGenes rasMultivariate Analysisprognosisbusiness
researchProduct

A second family with familial AD and the V717L APP mutation has a later age at onset

2006

Four mutations have been reported at the 717 codon of the amyloid precursor protein (APP), with valine substituted by isoleucine, glycine, phenylalanine, and leucine. While several families with the isoleucine substitution have been described, the other substitutions have been reported in only one family each worldwide. A family with the V717L APP mutation has been previously reported,1 with a mean age at onset of 38 years (range 35 to 39), based on four affected family members, and a mean age at death of 46 years (range 40 to 50). We have identified a second family with a later mean age at onset of 50 years (range 48 to 57) and mean age at death of 61 years (range 57 to 68). Family 171 is …

MalePediatricsmedicine.medical_specialtyMutation Missensemedicine.disease_causeAmyloid beta-Protein PrecursorAlzheimer DiseaseValineInternal medicinemedicineAmyloid precursor proteinHumansAge of OnsetAgedAge of Onset Aged Alzheimer Disease/genetics Alzheimer Disease/physiopathology Amino Acid Substitution Amyloid beta-Protein Precursor/genetics Female Humans Malle Middle Aged Mutation Missense PedigreeMutationSettore M-PSI/02 - Psicobiologia E Psicologia FisiologicabiologyMean ageMiddle AgedPedigreeEndocrinologyAmino Acid Substitutionbiology.proteinFemaleNeurology (clinical)IsoleucineNeurology
researchProduct

BRAF V600E Mutation in Two Distinct Meningeal Melanocytomas Associated With a Nevus of Ota

2014

MaleProto-Oncogene Proteins B-rafCancer ResearchSkin NeoplasmsAdolescentGlutamic AcidNevus of OtaValineMeningeal NeoplasmsmedicineHumansMelanomabusiness.industryValinemedicine.diseaseNevus of OtaBRAF V600ECell Transformation NeoplasticOncologyMutationMutation (genetic algorithm)Cancer researchMelanocytesSignal transductionbusinessSignal TransductionJournal of Clinical Oncology
researchProduct

Concordance of assays designed for the quantification of JAK2V617F: a multicenter study

2008

Background Many different techniques have been designed for the quantification of JAK2 V617F allelic burden, sometimes producing discrepant results. Design and Methods JAK2 V617F quantification techniques were compared among 16 centers using 11 assays based on quantitative polymerase chain reaction (with mutation-specific primers or probes, or fluorescent resonance energy transfer/melting curve analysis), allele-specific polymerase chain reaction, conventional sequencing or pyrosequencing. Results A first series of blinded samples (granulocyte DNA, n=29) was analyzed. Seven assays (12 centers) reported values inside the mean±2SD; the mean coefficient of variation was 31%. Sequencing techniq…

MaleSerial dilutionPhenylalanineCoefficient of variationBiologyMelting curve analysislaw.inventionlawhemic and lymphatic diseasesTaqManHumansAllelesPolymerase chain reactionValineOriginal ArticlesHematologyJanus Kinase 2Molecular biologyPedigreePhenotypeReal-time polymerase chain reactionMutationPyrosequencingFemalePrimer (molecular biology)Thrombocythemia EssentialHaematologica
researchProduct

Thymidylate synthases from Hymenolepis diminuta and regenerating rat liver: purification, properties, and inhibition by substrate and cofactor analog…

1995

Comparative studies of thymidylate synthases, isolated from the tapeworm, Hymenolepis diminuta, and regenerating liver of its host, rat, aimed at a possibility of specific inhibition of the helminthic enzyme, are presented. While similar in structure (dimers with monomer molecular masses of 33.7 kDa and 34.9 kDa, respectively) and parameters describing interactions with substrates and products, the tapeworm and rat enzymes differed in the dependences of reaction velocity on temperature (Arrhenius plots biphasic and linear, respectively). The tapeworm, compared with the host, enzyme was less sensitive to the competitive slow-binding inhibition by 5-fluoro-dUMP and its 2-thio congener, but eq…

MaleStereochemistryBiophysicsBiochemistryThymidylate synthaseCofactorchemistry.chemical_compoundmethylenetetrahydrofolate analoguesNon-competitive inhibitionStructural BiologyValineFluorodeoxyuridylateAnimalsRats WistardUMPenzyme inhibitionMolecular BiologyTetrahydrofolatesHelminthic enzymechemistry.chemical_classificationAlaninebiologyTemperatureThymidylate SynthaseHymenolepis diminutabiology.organism_classificationLiver RegenerationRatsMolecular WeightKineticsEnzymechemistryBiochemistryLiverbiology.proteinNorvalineanalogues(H. diminuta)HymenolepisBiochimica et biophysica acta
researchProduct

Short-term adaptation of conditioned fear responses through endocannabinoid signaling in the central amygdala

2010

International audience; Both, the cannabinoid receptor type 1 (CB1) and the central nucleus of the amygdala (CeA) are known to play crucial roles in the processing of fear and anxiety, whereby they appear to be especially involved in the control of fear states. However, in contrast to many other brain regions including the cortical subregions of the amygdala, the existence of CB1 in the CeA remains enigmatic. Here we show that CB1 is expressed in the CeA of mice and that CB1 in the CeA mediates short-term synaptic plasticity, namely depolarization-induced suppression of excitation (DSE) and inhibition (DSI). Moreover, the CB1 antagonist AM251 increased both excitatory and inhibitory postsyn…

MaleTime FactorsAction PotentialsAnxietyExtinction PsychologicalGABA AntagonistsPropanolaminesMice0302 clinical medicinePiperidinesReceptor Cannabinoid CB1Adaptation PsychologicalConditioning PsychologicalMoodFear conditioningHabituationStress DisordersMice Knockout0303 health sciencesBehavior AnimalCentral nucleus of the amygdalaValineFearExtinctionAmygdalaPyridazinesPsychiatry and Mental healthmedicine.anatomical_structureOriginal ArticlePsychologypsychological phenomena and processesSignal TransductionSensory Receptor CellsNeurophysiologyIn Vitro TechniquesInhibitory postsynaptic potentialAmygdala03 medical and health sciencesQuinoxalinesCannabinoid Receptor ModulatorsmedicineAnimalsMaze Learning030304 developmental biologyPharmacologyFear processing in the brainLearning & MemoryCannabinoidsExtinction (psychology)Phosphinic AcidsElectric StimulationMice Inbred C57BLGene Expression Regulationnervous systemSynaptic plasticityPyrazolesNeuroscienceExcitatory Amino Acid Antagonists030217 neurology & neurosurgeryEndocannabinoidsConditioning
researchProduct

Characterization of New Organic Nitrate Hybrid Drugs Covalently Bound to Valsartan and Cilostazol

2012

Background and Purpose: Organic nitrates represent a group of nitrovasodilators that are clinically used for the treatment of ischemic heart disease. With the present studies we synthesized and characterized new organic nitrate hybrid molecules. Compounds CLC-1265 (valsartan mononitrate) and CLC-1280 (valsartan dinitrate) are derivatives of the angiotensin receptor blocker valsartan, with CLC-1265 containing a single organic nitrate linker and CLC-1280 also containing a second, different linker. Compounds CLC-2000 (cilostazol mononitrate) and CLC-2100 (cilostazol dinitrate) are nitrate derivatives of the phosphodiesterase III inhibitor cilostazol. All compounds are designed as hybrid molecu…

MaleVasodilator AgentsTetrazoleschemistry.chemical_elementmedicine.disease_causeOxygenchemistry.chemical_compoundNitratemedicineAnimalsOrganic chemistryRats WistarPharmacologyNitratesValineGeneral MedicineIn vitroCilostazolRatsCilostazolOxidative StressValsartanchemistryVasoconstrictionCovalent bondValsartanLinkerPlatelet Aggregation InhibitorsOxidative stressmedicine.drugPharmacology
researchProduct